Boston Biotech nChroma Bio Halts Its Only Clinical Trial and Cuts About Half Its Staff

Boston's nChroma Bio said Wednesday, Nov. 18, it stopped dosing in its only trial, a hepatitis B study, and is cutting about half its staff. What we know.

Share this article

Featured photo: Disposable pipette tips in laboratory tip boxes (file photo; not an nChroma Bio lab). Photo: Gannu03, Wikimedia Commons, CC BY-SA 4.0.

Boston genetic medicines company nChroma Bio has stopped enrolling and dosing patients in its only clinical trial, an early-stage study of its chronic hepatitis B therapy CRMA-1001, and is restructuring while it weighs strategic alternatives for its other programs. The company announced the move in a LinkedIn post on Wednesday, Nov. 18.[1][2] The restructuring will cut about half of the company’s workforce, Endpoints News and the Boston Business Journal reported, as cited by BioSpace and The Pharma Letter.[1][2]

~50%
of staff cut, as reported by Endpoints and the BBJ
9
trial participants listed on ClinicalTrials.gov
51-200
employees, per the company’s LinkedIn page
Jan. 28
date nChroma announced its first patient dosed

Related: Watertown Biotech EyePoint to Cut About Half Its Staff After Wet AMD Trial Miss.

Advertisement

What we know

The halted study is a Phase 1/2 trial of CRMA-1001, a liver-directed epigenetic therapy for chronic hepatitis B. It was the company’s lone clinical program.[1] nChroma gave no reason for stopping enrollment and dosing, and it disclosed no clinical results.[2]

The company did not put a figure on the job cuts in its post.[2] It also did not give its headcount to Endpoints News. Its LinkedIn page lists a company size of 51 to 200 employees, so a cut of about half would mean somewhere between roughly 25 and 100 jobs, depending on where the company sits in that range (TBR calculation).[1]

Patients who already received CRMA-1001 will continue to be monitored, the company told Endpoints. ClinicalTrials.gov lists nine participants.[1]

A short run in the clinic

The trial began less than a year ago. nChroma announced on Dec. 16, 2025, that it had received authorization of a clinical trial application to start a first-in-human study of CRMA-1001, and on Jan. 28, 2026, it announced that the first patient had been dosed.[3] At the time, the company said additional enrollment was underway.[1]

The therapy is an epigenetic silencer, designed to switch off hepatitis B viral DNA. The company presented preclinical research on the approach at the American Association for the Study of Liver Diseases meeting in November 2025, and it posted further hepatitis B research as recently as September.[3]

Advertisement

What is left in the pipeline

Beyond CRMA-1001, nChroma has two research-stage programs and one at the candidate-enabled stage, a PCSK9 program for cardiometabolic disease.[1] The company’s remaining programs include a second hepatitis B candidate, The Pharma Letter reported.[2] nChroma has not said which of those programs it will prioritize or what strategic alternatives it is considering.

Why it matters for Boston

The cuts follow a similar move in October by Watertown’s EyePoint, which said it would cut about half its staff after a trial miss. BioSpace’s 2026 layoff tracker, which logged the nChroma cuts on Nov. 19, also lists Charles River Laboratories closing its Worcester site and consolidating at its Shrewsbury location.[1] For more on the region’s companies and jobs, see our Business & Finance coverage.

Sources

  1. BioSpace: Layoff Tracker: nChroma halves workforce, BioXcel lets execs go (Nov. 19, 2026)
  2. The Pharma Letter: nChroma Bio stops enrollment and dosing in hepatitis B trial (Nov. 20, 2026)
  3. nChroma Bio: News & Research, including press releases of Dec. 16, 2025 and Jan. 28, 2026 (accessed Nov. 20, 2026)

About the reporter: Michael Haverford is an AI reporter covering business, finance and technology for The Boston Report. This article was produced with AI under our editorial policy. Read our AI and media disclosure.

Read next in Boston Local News

Get The Boston Report Briefing

Our free weekly email with the most important stories from Boston and the world. Unsubscribe anytime.

Free. We never sell your address. Privacy policy

Get The Boston Report Briefing
Our free weekly email with the most important stories from Boston and the world. Unsubscribe anytime.
Sign up